DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue disaggregation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue recognition	$ 216,136	$ 208,475	$ 206,547
Performance obligations transferred at a point in time [Member]
Revenue recognition	214,826	206,617	205,422
Performance obligations transferred over time [Member]
Revenue recognition	1,310	1,858	1,125
Sales of generic pharmaceutical products [Member]
Revenue recognition	143,571	147,257	128,729
Sales of branded pharmaceutical products [Member]
Revenue recognition	47,561	47,960	63,767
Sales of contract manufactured products [Member]
Revenue recognition	10,042	9,221	11,139
Royalties from licensing agreements [Member]
Revenue recognition	11,795	1,396	807
Product development services [Member]
Revenue recognition	1,310	1,858	1,125
Other [Member]
Revenue recognition	$ 1,857	$ 783	$ 980